ReOx

ReOx is a biotechnology company dedicated to the discovery and development of small molecule therapeutics that modulate the oxygen-sensing pathway. The company was founded by Nobel Prize winner Sir Peter Ratcliffe and his colleagues from the University of Oxford, who pioneered the understanding of how cells sense and adapt to oxygen availability. ReOx focuses on targeting the Hypoxia-Inducible Factor (HIF) system, specifically through the inhibition of prolyl hydroxylases and factor-inhibiting HIF (FIH) enzymes. Their research platform leverages deep structural and chemical biology expertise to create highly selective modulators of these oxygen-sensing enzymes. The company's pipeline aims to address significant unmet needs in oncology, hematology, and inflammatory diseases by leveraging the body's fundamental physiological response to hypoxia.